Clinical Trial Update: A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations [Phase 4]

View source ↗

Summary

Phase 4 study evaluating Tarceva (erlotinib) in patients with EGFR-mutant locally advanced or metastatic non-small cell lung cancer. Results from a completed tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 4 | Status: COMPLETED | Results posted: 2015-06-02